2. Signaling Pathways
  3. Metabolic Enzyme/Protease
  4. Hexokinase

Hexokinase

Hexokinase

Related Products

PDF 0.1 MB

Hexokinases (HK) play a central role in cellular glucose metabolism. Hexokinasescatalyse the first obligatory step of glucose metabolism, the ATP-dependent phosphorylation of glucose (Glc) to yield glucose-6-phosphate (Glc-6-P). In addition to maintaining the downhill concentration gradient that permits facilitated glucose entry into cells, this reaction constitutes the first step of all major pathways of glucose utilization, including glycolysis, the pentose phosphate pathway, (PPP) and glycogenesis. As such hexokinases are uniquely positioned to influence the extent and direction of glucose flux within the cell. The PPP represents the principal cellular source of NADPH and plays important roles in redox homeostasis, anabolism and nucleotide synthesis (Rib-5-P, ribulose 5-phosphate). Similarly, glycolysis and glycogenesis play important roles in energy metabolism and storage, respectively. Other important cellular functions, including hexosamine and nucleotide sugar generation for glycosaminoglycan and glycoprotein biosynthesis, also require Glc-6-P as a precursor (UDP-Glc, uridine diphosphate glucose; UDP-GlcNAc, uridine diphosphate N-acetylglucosamine).

Cat. No. Product Name Effect Purity Chemical Structure
  • HY-13966
    2-Deoxy-D-glucose
    		Inhibitor 99.93%
    2-Deoxy-D-glucose is a glucose analog that acts as a competitive inhibitor of glucose metabolism, inhibiting glycolysis via its actions on hexokinase.
    2-Deoxy-D-glucose
  • HY-19992
    3-Bromopyruvic acid
    		Inhibitor 98.0%
    3-Bromopyruvate (Bromopyruvic acid) is an analogue of pyruvate and a potent hexokinase (HK)-II inhibitor with high tumor selectivity. 3-Bromopyruvate inhibits cell growth and induces apoptosis through interfering with glycolysis. 3-Bromopyruvate induces autophagy by stimulating ROS formation in breast cancer cells. Antimicrobial activities.
    3-Bromopyruvic acid
  • HY-B0486
    Lonidamine
    		Inhibitor 99.91%
    Lonidamine (AF-1890) is a hexokinase and mitochondrial pyruvate carrier inhibitor (Ki: 2.5 μM). Lonidamine also inhibits aerobic glycolysis in cancer cells. Lonidamine can be used in the research of mitochondrial metabolism and inflammation, such as pulmonary fibrosis.
    Lonidamine
  • HY-155008
    PROTAC HK2 Degrader-1
    		Degrader 99.76%
    PROTAC HK2 Degrader-1 is a PROTAC consisting of Lonidamine (HY-B0486) as a target protein Hexokinase 2 (HK2) inhibitor and Thalidomide (HY-14658) as a CRBN ligand-linked PROTAC. PROTAC HK2 Degrader-1 selectively inhibits the proliferation of breast cancer cells by forming a ternary complex through the ubiquitin-proteasome system to degrade Hexokinase 2 (HK2) protein leading to mitochondrial damage and cell death. PROTAC HK2 Degrader-1 effectively inhibits breast tumor growth and reduces the colonic side effects of cisplatin for breast cancer research.
    PROTAC HK2 Degrader-1
  • HY-134929
    Benitrobenrazide
    		Inhibitor 99.91%
    Benitrobenrazide (BNBZ) is the orally active inhibitor for hexokinase 2 with an IC50 of 0.53 µM. Benitrobenrazide causes DNA damage, and exhibits antitumor effect.
    Benitrobenrazide
  • HY-180805
    HK2-IN-3
    		Inhibitor
    HK2-IN-3 (compound 12) is a potent hexokinase 2 (HK2) inhibitor with an IC50 of 56.4 nM. HK2-IN-3 reduces glucose uptake and downregulated GLUT1/GLUT4 in oral squamous cell carcinoma (OSCC). HK2-IN-3 induces mitophagy and apoptosis. HK2-IN-3 suppresses tumor growth and angiogenesis in OSCC xenograft mouse models. HK2-IN-3 can be used for OSCC research.
    HK2-IN-3
  • HY-183809
    ZSW
    		Inhibitor
    ZSW is a hexokinase 2 (HK2) inhibitor with human HK2 IC50 of 0.48 μM, human HK2 Ka of 252.00 μM, and selectivity over HK3 and GCK. ZSW binds directly to HK2, inhibits its enzymatic activity, modulates macrophage phenotypes through glycolysis inhibition, and inhibits NF-κB nuclear translocation by preventing IκBα phosphorylation and degradation. ZSW alleviates inflammatory bowel disease (IBD) and improves the intestinal inflammatory state of IBD mice. ZSW can be used for the research of inflammatory bowel disease.
    ZSW
  • HY-15947G
    Ravoxertinib (GMP)
    		Inhibitor
    Ravoxertinib GMP is Ravoxertinib (HY-15947) produced by using GMP guidelines. GMP small molecules works appropriately as an auxiliary reagent for cell therapy manufacture. Ravoxertinib (GDC-0994) is an orally active ERK1/2 inhibitor. Ravoxertinib inhibits the ERK1/2 MAPK signaling pathway and reduces the expression levels of c-Myc, HK2 and LDHA. Ravoxertinib decreases mammosphere formation, and exerts additive and/or superadditive cytotoxicity when combined with Ipatasertib (HY-15186) in 3D tumor sphere models. Ravoxertinib can be used in research related to various cancers including breast cancer, melanoma, head and neck cancer, non-small cell lung cancer, ovarian cancer and Merkel cell carcinoma.
    Ravoxertinib (GMP)
  • HY-U00462
    D-Mannoheptulose
    		Inhibitor 99.90%
    D-Mannoheptulose is a 7-carbon keto sugar found in avocado. D-mannoheptulose is a specific inhibitor of D-glucose phosphorylation by hexokinase isoenzymes. D-Mannoheptulose can block insulin release and utilization of carbohydrate in rat. D-Mannoheptulose has various functions as anti-oxidants, anticancer effects and energy sources.
    D-Mannoheptulose
  • HY-P10108
    Hexokinase II VDAC binding domain peptide, cell-permeable
    		Inhibitor 99.97%
    Hexokinase II VDAC binding domain peptide (Hxk2VBD peptide) is a cell-permeable hexokinase II VDAC binding domain. Hexokinase II VDAC binding domain peptide inhibits mitochondrial localization of hexokinase 2 (HXK2). Hexokinase II VDAC binding domain peptide inhibits neurotrophic factor-directed axon outgrowth.
    Hexokinase II VDAC binding domain peptide, cell-permeable
  • HY-139409A
    2-Deoxy-D-glucose 6-phosphate disodium
    		Inhibitor 98.0%
    2-Deoxy-D-glucose 6-phosphate disodium is an ATP-competitive, 2-deoxy-D-glucose non-competitive Hexokinase inhibitor, with a Ki value of 1.45 mM against bovine heart hexokinase. 2-Deoxy-D-glucose 6-phosphate disodium exerts ATP-competitive and 2-deoxy-D-glucose non-competitive inhibitory effects on bovine heart hexokinase. 2-DG inhibits glycolysis via the production and intracellular accumulation of 2-Deoxy-D-glucose 6-phosphate disodium, thereby inhibiting the functions of hexokinase and Glucose-6-phosphate isomerase, and inducing cell death. 2-Deoxy-D-glucose 6-phosphate disodium can be used in cancer-related research.
    2-Deoxy-D-glucose 6-phosphate disodium
  • HY-13966S
    2-Deoxy-D-glucose-d
    		98.0%
    2-Deoxy-D-glucose-d is the deuterium labeled 2-Deoxy-D-glucose. 2-Deoxy-D-glucose is a glucose analog that acts as a competitive inhibitor of glucose metabolism, inhibiting glycolysis via its actions on hexokinase.
    2-Deoxy-D-glucose-d
  • HY-175035
    HK-2-IN-1
    		Inhibitor 99.88%
    HK-2-IN-1 is a Hexokinase 2 (HK-2) inhibitor. HK-2-IN-1 exhibits a non-activating effect on human recombinant HK-2 enzyme. HK-2-IN-1 has anti-tumor activity, affecting immune cells in the tumor microenvironment. HK-2-IN-1 has immunomodulatory effects and is potentially useful in the study of cancers such as colon cancer, liver cancer, and breast cancer.
    HK-2-IN-1
  • HY-13966S2
    2-Deoxy-D-glucose-13C
    		99.48%
    2-Deoxy-D-glucose-13C is the 13C labeled 2-Deoxy-D-glucose. 2-Deoxy-D-glucose is a glucose analog that acts as a competitive inhibitor of glucose metabolism, inhibiting glycolysis via its actions on hexokinase.
    2-Deoxy-D-glucose-<sup>13</sup>C
  • HY-W000133
    Metrizamide
    		Inhibitor 99.0%
    Metrizamide (Amipaque) is used as the contrast medium for angiography in neuroradiological investigations. Metrizamide inhibits human brain hexokinase.
    Metrizamide
  • HY-B0486R
    Lonidamine (Standard)
    		Inhibitor
    Lonidamine (Standard) is the analytical standard of Lonidamine. This product is intended for research and analytical applications. Lonidamine (AF-1890) is a hexokinase and mitochondrial pyruvate carrier inhibitor (Ki: 2.5 μM). Lonidamine also inhibits aerobic glycolysis in cancer cells. Lonidamine can be used in the research of mitochondrial metabolism and inflammation, such as pulmonary fibrosis.
    Lonidamine (Standard)
  • HY-13966S4
    2-Deoxy-D-glucose-13C-1
    2-Deoxy-D-glucose-13C-1 is the 13C labeled 2-Deoxy-D-glucose. 2-Deoxy-D-glucose is a glucose analog that acts as a competitive inhibitor of glucose metabolism, inhibiting glycolysis via its actions on hexokinase.
    2-Deoxy-D-glucose-<sup>13</sup>C-1
  • HY-P2776C
    Hexokinase, Saccharomyces cerevisiae
    Hexokinase, Saccharomyces cerevisiae (EC 2.7.1.1), is a naturally occurring *Saccharomyces cerevisiae* hexokinase used in studies of glucose metabolism and enzymatic mechanisms.
    Hexokinase, Saccharomyces cerevisiae
  • HY-168717
    HK-2-IN-2
    		Inhibitor
    HK2-IN-2 (Compound 26) is a Hexokinase 2 inhibitor that demonstrates significant anti-tumor activity by targeting microtubules and Hexokinase 2, with an IC50 value of 0.764 μM against MD-MBA-231 cells. HK2-IN-2 effectively inhibits the activity of Hexokinase 2, leading to the accumulation of Reactive Oxygen Species and dysfunction of the mitochondrial membrane potential (MMP), thereby promoting apoptosis and blocking the cell cycle.
    HK-2-IN-2
  • HY-182243
    HK2-IN-4
    		Inhibitor
    HK2-IN-4 is a selective hexokinase 2 (HK2) inhibitor with an IC50 value of 0.79 μM and a Kd value of 0.41 μM. HK2-IN-4 blocks the interaction between HK2 and voltage-dependent anion channel 1 (VDAC1). HK2-IN-4 reduces lactate and ATP levels in cancer cells. HK2-IN-4 induces the production of apoptosis (apoptosis) markers in cancer cells, including increased p-AMPK/AMPK ratio and Bax levels, as well as decreased Bcl2 levels. HK2-IN-4 inhibits the proliferation of cancer cells with high HK2 expression. HK2-IN-4 can be used in research related to colorectal cancer and non-small cell lung cancer.
    HK2-IN-4
Cat. No. Product Name / Synonyms Application Reactivity